Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
评估Janux Therapeutics：来自6位财务分析师的见解
Investigating Analyst Ratings...In the preceding three months, 6 analysts have released ratings for Janux Therapeutics (NASDAQ:JANX), presenting a wide array of perspectives from bullish to bearish.
在过去三个月中，有6位分析师为Janux Therapeutics（纳斯达克：JANX）发布了评级，从看好到看淡，呈现了多种不同观点。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析师最近的评级概述，为了全面了解过去30天的情绪变化并与前几个月进行比较，提供了深入的见解。
In the assessment of 12-month price targets, analysts unveil insights for Janux Therapeutics, presenting an average target of $80.17, a high estimate of $100.00, and a low estimate of $63.00. This current average has decreased by 8.55% from the previous average price target of $87.67.
在评估为期12个月的价格目标时，分析师揭示了关于Janux Therapeutics的见解，提出了平均目标价80.17美元，高估价100.00美元，低估价63.00美元。当前的平均目标价较上一次的87.67美元的平均目标价下降了8.55%。
Investigating Analyst Ratings...
分析师...
登录免费看全文
登录/注册
资讯热榜
更新时间